In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Merck & Co. acquires remaining 49% of Banyu

10 Dec 2007

Executive Summary

Merck & Co., through its Merck Sharp & Dohme Japanese subsidiary, will acquire the remaining 49% of Banyu Pharmaceutical that it does not already own (about 130mm shares) for $1.5bn (Yen180.9bn).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By